MA46567A - Formes cristallines de l'éravacycline - Google Patents

Formes cristallines de l'éravacycline

Info

Publication number
MA46567A
MA46567A MA046567A MA46567A MA46567A MA 46567 A MA46567 A MA 46567A MA 046567 A MA046567 A MA 046567A MA 46567 A MA46567 A MA 46567A MA 46567 A MA46567 A MA 46567A
Authority
MA
Morocco
Prior art keywords
eravacycline
crystalline forms
crystalline
forms
eravacycline crystalline
Prior art date
Application number
MA046567A
Other languages
English (en)
Inventor
Chi-Li Chen
Minsheng He
Philip C Hogan
Danny Lafrance
Yansheng Liu
John Niu
Original Assignee
Tetraphase Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetraphase Pharmaceuticals Inc filed Critical Tetraphase Pharmaceuticals Inc
Publication of MA46567A publication Critical patent/MA46567A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA046567A 2016-10-19 2017-10-19 Formes cristallines de l'éravacycline MA46567A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662410230P 2016-10-19 2016-10-19

Publications (1)

Publication Number Publication Date
MA46567A true MA46567A (fr) 2019-08-28

Family

ID=60263035

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046567A MA46567A (fr) 2016-10-19 2017-10-19 Formes cristallines de l'éravacycline

Country Status (15)

Country Link
US (3) US10961190B2 (fr)
EP (1) EP3529236B1 (fr)
JP (2) JP7492335B2 (fr)
KR (2) KR102660864B1 (fr)
CN (2) CN110582486B (fr)
DK (1) DK3529236T3 (fr)
ES (1) ES2978198T3 (fr)
HR (1) HRP20240605T1 (fr)
HU (1) HUE066360T2 (fr)
MA (1) MA46567A (fr)
PH (1) PH12019500822A1 (fr)
PL (1) PL3529236T3 (fr)
SG (1) SG11201903327PA (fr)
SI (1) SI3529236T1 (fr)
WO (1) WO2018075767A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712476T3 (es) 2012-08-31 2019-05-13 Tetraphase Pharmaceuticals Inc Compuestos de tetraciclina
EP3390358B1 (fr) 2016-01-22 2020-09-23 Sandoz AG Bis-hydrochlorure cristalin d'eravacycline
SI3529236T1 (sl) 2016-10-19 2024-08-30 Tetraphase Pharmaceuticals, Inc. Kristalinične oblike eravaciklina
WO2023233397A1 (fr) * 2022-05-29 2023-12-07 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Éravacycline pour le traitement du cancer
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935384A (en) 1959-03-30 1963-08-28 Pfizer & Co C Tetracycline derivatives and preparation thereof
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
GB1034933A (en) 1962-10-29 1966-07-06 American Cyanamid Co 4-demethylamino-4-substituted amino 6-demethyl tetracyclines
US3364123A (en) 1963-05-06 1968-01-16 Squibb & Sons Inc Production of 4n-demethyl-4n-ethyl tetracyclines
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
GB1065715A (en) 1964-04-16 1967-04-19 Pfizer & Co C Tetracycline derivatives
US3247226A (en) 1964-07-06 1966-04-19 American Cyanamid Co 4-dimethylamino and 4-hydroxytetracycloxides
US3394178A (en) 1965-01-26 1968-07-23 Merck & Co Inc Nu-ethyloxytetracycline
GB1077598A (en) 1965-05-12 1967-08-02 Pfizer & Co C Preparation of n-demethyl tetracyclines
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
US3433709A (en) 1965-12-07 1969-03-18 American Cyanamid Co Biological transformation of alpha-6-deoxytetracyclines to tetracyclines
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3824285A (en) 1967-09-13 1974-07-16 Pfizer 4-oxo-4-dedimethylaminotetracycline-4,6-hemiketals
US3947517A (en) 1969-06-12 1976-03-30 Research Corporation Stereoselective introduction of tetracyclines hydroxyl group at 12(a) position in synthesis of tetracyclines
DE2437487A1 (de) 1974-08-03 1976-02-19 Merck Patent Gmbh 7-methoxy-6-thia-tetracycline und verfahren zu ihrer herstellung
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
YU290176A (en) 1976-11-26 1982-05-31 Pliva Zagreb Process for preparing 4-dedimethylamino-4-arylsulfonamido-5a,6-anhydrotetracycline
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
DE69232302D1 (de) 1991-10-04 2002-01-31 American Cyanamid Co 7-Substituierte-9-substituierte Amino-6-Demethyl-6-Deoxy-Tetracycline
USRE40183E1 (en) 1991-10-04 2008-03-25 Wyeth Holdings Corporation 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
SG47520A1 (en) 1992-08-13 1998-04-17 American Cyanamid Co New method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
JPH06256280A (ja) 1992-11-17 1994-09-13 Univ New York State 糖尿病における過度のコラーゲン架橋結合を阻害する非抗菌性化学修飾テトラサイクリンを含むテトラサイクリン
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5371076A (en) 1993-04-02 1994-12-06 American Cyanamid Company 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
MX9603508A (es) 1994-02-17 1997-03-29 Pfizer Analogos de la doxiciclina.
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
WO1999037307A1 (fr) 1998-01-23 1999-07-29 Trustees Of Tufts College Composes actifs du point de vue pharmaceutique et leurs methodes d'utilisation
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
JP2002525299A (ja) 1998-09-28 2002-08-13 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク 新規白内障形成抑制剤
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001098260A1 (fr) 2000-06-16 2001-12-27 Trustees Of Tufts College Composes de phenyl tetracycline 7-n-substituee
EP1301467B1 (fr) 2000-07-07 2006-08-16 Trustees Of Tufts College Composes de monocycline 9-substitues
KR100619637B1 (ko) 2000-07-07 2006-09-12 트러스티즈 오브 터프츠 칼리지 7-치환 테트라사이클린 화합물
EP1303479B1 (fr) 2000-07-07 2011-04-06 Trustees Of Tufts College Composes de tetracycline substitues en 7, 8 et 9
EP2301914A1 (fr) 2001-03-13 2011-03-30 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués en position 7, 9
EP1379255A2 (fr) 2001-03-14 2004-01-14 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues, en tant qu'agents antifongiques
WO2002072031A2 (fr) 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2002085303A2 (fr) 2001-04-24 2002-10-31 Paratek Pharmaceuticals, Inc. Composes de tetracycline substitues destines au traitement de la malaria
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
JP2004537544A (ja) 2001-07-13 2004-12-16 パラテック ファーマシューティカルズ インコーポレイテッド 標的治療活性を有するテトラサイクリン化合物
US7056902B2 (en) 2002-01-08 2006-06-06 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EA013819B1 (ru) 2002-03-08 2010-08-30 Паратек Фармасьютикалс, Инк. Аминометилзамещенные тетрациклиновые соединения
EA200401232A1 (ru) 2002-03-21 2005-12-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
EP1534300A4 (fr) 2002-07-12 2008-04-23 Paratek Pharm Innc Composes de tetracycline substituee en 3, 10, et 12a
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
JP2006503898A (ja) 2002-10-24 2006-02-02 パラテック ファーマシューティカルズ， インク． マラリア治療のための置換テトラサイクリン化合物
EA200600221A1 (ru) 2003-07-09 2006-06-30 Пэрэтек Фамэсьютикэлс, Инк. Замещённые соединения тетрациклина (варианты), фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
WO2005082860A1 (fr) 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines et leur utilisation en tant qu'inhibiteurs de la calpaine
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
PL1753713T3 (pl) 2004-05-21 2017-02-28 President And Fellows Of Harvard College Synteza tetracyklin oraz ich analogów
EP2284150A3 (fr) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Composés de tétracycline substituée
EP2301916A3 (fr) 2004-10-25 2011-09-28 Paratek Pharmaceuticals, Inc. 4-aminotétracyclines et procédés d'utilisation associés
CA2597212A1 (fr) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. Derives 11a, 12 de composes de tetracycline
EP1848686A2 (fr) 2005-02-15 2007-10-31 Wyeth Tetracyclines 9-substituees
JP2009502809A (ja) 2005-07-21 2009-01-29 パラテック ファーマシューティカルズ インコーポレイテッド １０−置換テトラサイクリンおよびその使用方法
WO2007087416A2 (fr) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Procede permettant d'accroitre la biodisponibilite orale de tetracyclines
US8486921B2 (en) 2006-04-07 2013-07-16 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
EP2029749A2 (fr) 2006-05-15 2009-03-04 Paratek Pharmaceuticals, Inc. Méthodes de régulation de l'expression de gènes ou de produits géniques à l'aide de composés de tétracycline substituée
EP3056487B1 (fr) 2006-10-11 2018-02-21 President and Fellows of Harvard College Synthèse d'un intermédiaire de l'énone
WO2008045507A2 (fr) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Composés de tétracycline substitués utilisés pour le traitement d'infections à bacillus anthracis
PL2109602T3 (pl) 2006-12-21 2014-09-30 Paratek Pharm Innc Pochodne tetracyliny do leczenia zakażeń bakteryjnych, wirusowych i pasożytniczych
AU2008239606A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
EA201070233A1 (ru) 2007-07-06 2010-08-30 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
WO2009073056A1 (fr) 2007-09-07 2009-06-11 Dr. Reddy's Laboratories Ltd. Nouveaux dérivés de tétracycline utiles en tant qu'agents antibactériens
WO2009128913A1 (fr) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Composés à base de tétracyclines substituées
EP2307027A4 (fr) 2008-07-11 2012-08-15 Neumedics Dérivés de tétracycline présentant une activité antibiotique réduite et des bénéfices neuroprotecteurs
HUE026562T2 (hu) 2008-08-08 2016-06-28 Tetraphase Pharmaceuticals Inc C7-fluor-helyettesített tetraciklin vegyületek
WO2010126607A2 (fr) 2009-04-30 2010-11-04 President And Fellows Of Harvard College Synthèse de tétracyclines et intermédiaires de celles-ci
WO2010129055A1 (fr) 2009-05-08 2010-11-11 Tetraphase Pharmaceuticals, Inc. Composés de 8-aza tétracycline
US9315451B2 (en) 2009-05-08 2016-04-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US20120115819A1 (en) 2009-05-13 2012-05-10 Clark Roger B Pentacycline Compounds
DK2470500T3 (en) 2009-08-28 2018-01-08 Tetraphase Pharmaceuticals Inc tetracycline
JP2013521314A (ja) 2010-03-10 2013-06-10 ユニバーシティー ヘルス ネットワーク 癌の処置のためのチゲサイクリンの使用
MX2012011453A (es) 2010-03-31 2013-02-15 Tetraphase Pharmaceuticals Inc Compuestos de tetraciclina policíclica.
TW201245116A (en) 2010-08-12 2012-11-16 Tetraphase Pharmaceuticals Inc Tetracycline analogs
WO2012047907A1 (fr) 2010-10-04 2012-04-12 President And Fellows Of Harvard College Synthèse de tétracyclines substituées en c5, leurs utilisations, et intermédiaires dans la synthèse de celles-ci
DK2707003T3 (da) * 2011-05-12 2019-08-05 Paratek Pharm Innc Krystallinske salte af (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacen-2-carboxylsyreamid og fremgangsmåder til anvendelse deraf
ES2712476T3 (es) 2012-08-31 2019-05-13 Tetraphase Pharmaceuticals Inc Compuestos de tetraciclina
MA40836A (fr) * 2014-10-23 2017-08-29 Tetraphase Pharmaceuticals Inc Procédures de semi-synthèse
WO2017097891A1 (fr) * 2015-12-10 2017-06-15 Sandoz Ag Éravacycline cristalline
EP3390358B1 (fr) 2016-01-22 2020-09-23 Sandoz AG Bis-hydrochlorure cristalin d'eravacycline
KR102558540B1 (ko) 2016-08-30 2023-07-21 테트라페이즈 파마슈티컬스, 인코포레이티드 테트라사이클린 화합물 및 치료 방법
SI3529236T1 (sl) * 2016-10-19 2024-08-30 Tetraphase Pharmaceuticals, Inc. Kristalinične oblike eravaciklina

Also Published As

Publication number Publication date
HRP20240605T1 (hr) 2024-07-19
KR20190065414A (ko) 2019-06-11
CN110582486B (zh) 2024-01-12
US11578044B2 (en) 2023-02-14
KR102660864B1 (ko) 2024-04-25
JP2019531321A (ja) 2019-10-31
JP2022186979A (ja) 2022-12-15
US20190256462A1 (en) 2019-08-22
ES2978198T3 (es) 2024-09-06
US20230416212A1 (en) 2023-12-28
JP7492335B2 (ja) 2024-05-29
PH12019500822A1 (en) 2019-08-19
KR20240058958A (ko) 2024-05-07
PL3529236T4 (pl) 2024-07-08
EP3529236B1 (fr) 2024-02-07
US10961190B2 (en) 2021-03-30
SG11201903327PA (en) 2019-05-30
US20210363103A1 (en) 2021-11-25
EP3529236A1 (fr) 2019-08-28
WO2018075767A1 (fr) 2018-04-26
HUE066360T2 (hu) 2024-07-28
DK3529236T3 (da) 2024-05-13
SI3529236T1 (sl) 2024-08-30
PL3529236T3 (pl) 2024-07-08
CN110582486A (zh) 2019-12-17
CN117903083A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
DK3435933T3 (da) Stomifastgørelse
MA51819A (fr) Nouvelles formes cristallines
ES1243880Y (es) Cepillo de dientes
MA47596A (fr) Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan
MA50657A (fr) Formulations de niraparib
MA46567A (fr) Formes cristallines de l'éravacycline
MA46717A (fr) Variantes de l'endonucléase homing tcra
MA51154A (fr) Variants de cd19
DK3829402T3 (da) Tæppe
DK3819287T3 (da) Amorft tapentadolphosphat
MA50068A (fr) Formulations de copanlisib
MA46266A (fr) Formes cristallines
FR3048695B1 (fr) Plaque de platre
CL2016001891S1 (es) Lentes de aumento
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
ES1229452Y (es) Disposición de filtración
FR3043318B1 (fr) Element d'encadrement de panneau
MA52458A (fr) Nouvelles formes cristallines
ES1138412Y (es) Recogedor de excrementos
CL2018001694S1 (es) Cepillo de dientes
IT201700090331A1 (it) "lopemide"
IT201700071679A1 (it) Remembebe'
UA39214S (uk) Культиватор навісний
ES1210115Y (es) Retrovisor anulador de ángulo muerto
UY4612S (es) Cepillo de dientes